<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01689792</url>
  </required_header>
  <id_info>
    <org_study_id>NOR-01/2011 (PDR)</org_study_id>
    <nct_id>NCT01689792</nct_id>
  </id_info>
  <brief_title>A Multi-centre Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)</brief_title>
  <official_title>A Multi-centre, Randomised, Investigator-blinded Study Comparing the Polyp Detection Rate of Two Different Types of Bowel Preparation: a 2-litre Solution (MOVIPREP®) Versus a Hyperosmotic and Stimulant Combined Low Volume Bowel Preparation (Sodium Picosulfate and Magnesium Citrate)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Norgine</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Norgine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To compare the polyp and adenoma detection rate of MOVIPREP versus an oral Sodium
      Picosulfate/Magnesium Citrate solution.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2011</start_date>
  <completion_date type="Actual">December 2013</completion_date>
  <primary_completion_date type="Actual">January 2013</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Screening</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Polyp detection rate</measure>
    <time_frame>At colonoscopy</time_frame>
    <description>Polyp detection rate defined as number of patients with at least one polyp or flat lesion as recorded by the endoscopist</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Adenoma Detection Rate (ADR)</measure>
    <time_frame>At the Colonoscopy</time_frame>
    <description>ADR, (including flat lesions) defined as number of patients with at least one adenoma as recorded by the pathologist in relation to the total analysis population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>ADR and PDR by location</measure>
    <time_frame>at the colonoscopy</time_frame>
    <description>ADR and PDR by location:
left sided (rectum, colon sigmoideum, colon decendens, left half of colon transversum
right-sided (right half of colon transversum, colon ascendens, caecum</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cancer detection rate</measure>
    <time_frame>at the colonoscopy</time_frame>
    <description>Cancer detection rate, defined as number of patients with at least one malignancy in relation to the total analysis population</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Flat lesion only detection rate</measure>
    <time_frame>at the colonoscopy</time_frame>
    <description>Flat lesion only detection of the patients</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Advanced risk lesion detection rate</measure>
    <time_frame>at the colonoscopy</time_frame>
    <description>Advanced risk lesion detection rate (lesions &gt;1 cm, low grade and/or villous</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colonoscopy completion rate</measure>
    <time_frame>at the colonoscopy</time_frame>
    <description>The rate of colonoscopy completion</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Colon cleansing quality</measure>
    <time_frame>at the colonoscopy</time_frame>
    <description>Colon cleansing quality as reported by the gastroenterologist, according to the Harefield Cleansing Scale©</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Acceptability and tolerability of medication using patient questionnaires</measure>
    <time_frame>Throughout the study</time_frame>
    <description>The acceptability and tolerability of the study medication taken by the patients throughout the study using specified patient questionnaires</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">398</enrollment>
  <condition>Colorectal Cancer</condition>
  <arm_group>
    <arm_group_label>CitraFleet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Administration of CitraFleet</description>
  </arm_group>
  <arm_group>
    <arm_group_label>MOVIPREP</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Administration of MOVIPREP</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>MOVIPREP</intervention_name>
    <arm_group_label>MOVIPREP</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>CitraFleet</intervention_name>
    <arm_group_label>CitraFleet</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patient's written informed consent must be obtained prior to inclusion.

          -  Male or female outpatients or inpatients aged 40 to 80 years with an indication for
             complete colonoscopy.

          -  Willing to undergo a colonoscopy for diagnostic or surveillance purposes

          -  Patients with a known personal of familial risk of colon neoplasia, willing to undergo
             a screening colonoscopy

          -  Willing, able and competent to complete the entire procedure and to comply with study
             instructions.

          -  Females of childbearing potential must employ an adequate method of contraception.

        Exclusion Criteria:

          -  History of gastric emptying disorders.

          -  History of ileus, toxic megacolon, gastrointestinal obstruction and colonic
             perforation.

          -  History of phenylketonuria.

          -  Known glucose-6-phosphate dehydrogenase deficiency.

          -  Known hypersensitivity to macrogol 3350, sodium sulphate or ascorbic acid/sodium
             ascorbate.

          -  History of colonic resection.

          -  Requirement for permanent medication and associated stable serum concentrations (e.g.
             neuroleptic drugs).

          -  Presence of congestive heart failure (NYHA III + IV).

          -  Acute life-threatening cardiovascular disease.

          -  Documented history of severe renal insufficiency (creatinine clearance &lt;30 ml/min).

          -  Other contraindication described in the summary of product characteristics (SmPC) of
             either preparation.

          -  Patient has a condition, clinically significant laboratory results, or is in a
             situation which, in the investigator's opinion, may put the patient at significant
             risk, may confound the study results, or may interfere significantly.

          -  Application of any unlicensed medication within the previous 3 months or participation
             in any other research study in the last 3 months.

          -  Females who are pregnant, nursing or planning a pregnancy.

          -  Patients who, in the opinion of the investigator, may not be compliant with the study
             requirements.

          -  Previous participation in this clinical study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Wolfgang Fishbach, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Klinikum Aschaffenburg-Alzenau</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Klinikum Aschaffenburg</name>
      <address>
        <city>Aschaffenburg</city>
        <zip>Am Hasenkopf 1</zip>
        <country>Germany</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Germany</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 12, 2012</study_first_submitted>
  <study_first_submitted_qc>September 20, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 21, 2012</study_first_posted>
  <last_update_submitted>March 30, 2015</last_update_submitted>
  <last_update_submitted_qc>March 30, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">March 31, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Colorectal Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Citric Acid</mesh_term>
    <mesh_term>Central Nervous System Stimulants</mesh_term>
    <mesh_term>Magnesium citrate</mesh_term>
    <mesh_term>Picosulfate sodium</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

